Lung Cancer Clinical Trials in Dallas

Showing 241-260 of 660 trials

Active Not RecruitingEARLY Phase 1< 1 mile

Ruxolitinib for Cancer Cachexia

NCT04906746

To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.

Stage IV Non-small Cell Lung CancerCachexia

Tu Dan10 participantsStarted Feb 2022

Dallas, Texas, United States

COMPLETEDPhase 3< 1 mile

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

NCT04026412

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb925 participantsStarted Oct 2019

La Jolla, California, United States • San Francisco, California, United States • San Francisco, California, United States +180 more locations

Ruxolitinib for Cancer Cachexia

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Lung Cancer Trials in Other Cities

A Study to Investigate LYL845 in Adults With Solid Tumors

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

AVID100 in Advanced Epithelial Carcinomas

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

A Study to Investigate LYL797 in Adults With Solid Tumors

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Medical Access Program for Patritumab Deruxtecan

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

MGC018 With or Without MGA012 in Advanced Solid Tumors

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Validation of a Multi-gene Test for Lung Cancer Risk

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Other Conditions in Dallas